CUSABIO has built a mature production system of monoclonal antibodies. Take this PKM monoclonal antibody for example. In the production, the mouses were immunized with Recombinant Human Pyruvate kinase PKM protein at first, and then the spleen cells of the mouse were obtained. Next, used cell hybridization technology to fuse myeloma cells and B lymphocytes in the spleen cells to generate hybridoma. And then screened the obtained hybridoma cells to select the ones that could secrete high-titer antibodies for the production of the PKM monoclonal antibody. This antibody was purified by Protein G and validated in ELISA, WB, IHC, IF, FC, IP.
PKM2 has two isozymes of M type and L type, and M type has M1 and M2 subtypes. M1 is distributed in myocardium, skeletal muscle, and brain tissue; M2 is widely present in tissues during the embryonic period. As the embryo develops, it is gradually replaced by other subtypes in some tissues, and is only highly expressed in cells with a high nucleic acid synthesis rate. , Especially in tumor cells, it is of great significance to the metabolism of cancer and the promotion of tumor formation. At the same time, in the process of tumor progression, due to tumor cell necrosis and metastasis, PKM2 will be released into the blood, and the PKM2 of gastrointestinal tumors It can also be excreted with the stool of cancer patients. Some studies have found that continuous monitoring of PKM2 levels in the plasma of patients with gastric cancer, non-small cell lung cancer, rectal cancer, breast cancer, hepatocellular carcinoma, and renal clear cell carcinoma Comparative analysis shows that the level of PKM2 is significantly increased in tumor patients, which will help the early diagnosis and prognostic judgment of these tumors. Therefore, PKM2 is also used as a very potential new tumor marker. It is expected to become an important anti-tumor drug target.